Showing results (31-40 of 127) with videos related to
Sort By:
Pageof 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
Phase II trial of vinflunine in relapsed small cell lung cancerDavid R Spigel, John D Hainsworth, Cassie M Lane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, Cindy Farley, et al.Cancer Investigation|April 8, 2011
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignanciesDavid Spigel, Suzanne Jones, John Hainsworth, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2005
Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research networkJohn D Hainsworth, Sharlene Litchy, Lisa H Morrissey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, James R Gray, Lisa H Morrissey, et al.European Journal of Cancer (Oxford, England : 1990)|February 3, 2020
The role of site-specific therapy for cancers of unknown of primary: A meta-analysisElie Rassy, Ziad Bakouny, Toni K Choueiri, et al.The Oncologist|April 30, 2010
Molecular profiling in unknown primary cancer: accuracy of tissue of origin predictionF Anthony Greco, David R Spigel, Denise A Yardley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancerHoward Burris, Denise Yardley, Suzanne Jones, et al.Clinical Breast Cancer|August 8, 2009
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancerDenise A Yardley, Howard A Burris, Sarah Hanson, et al.Lung Cancer (Amsterdam, Netherlands)|February 8, 2008
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancerF Anthony Greco, Philip Bonomi, Jeffrey Crawford, et al.Pageof 13